Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan-Jiang Xi Road, Guangzhou, 510120, People's Republic of China.
J Hematol Oncol. 2021 Nov 15;14(1):194. doi: 10.1186/s13045-021-01210-2.
The main cause of death in colorectal cancer patients is metastasis. Accumulating evidences suggest that circRNA plays pivotal roles in cancer initiation and development. However, the underlying molecular mechanisms of circRNAs that orchestrate cancer metastasis remain vague and need further clarification.
Two paired CRC and adjacent normal tissues were used to screen the upregulated circRNAs by circRNA-seq; then, cell invasion assay was applied to confirm the functional invasion-related circRNAs. According to the above methods, circHERC4 (hsa_circ_0007113) was selected for further research. Next, we investigated the clinical significance of circHERC4 in a large cohort of patients with CRC. The oncogenic activity of circHERC4 was investigated in both CRC cell lines and animal xenograft studies. Finally, we explored the molecular mechanisms underlying circHERC4 as a malignant driver.
We demonstrated that circHERC4 was aberrantly elevated in CRC tissues (P < 0.001), and was positively associated with lymph node metastasis and advanced tumor grade (P < 0.01). Notably, the expression of circHERC4 was associated with worse survival in patients with CRC. Silencing of circHERC4 significantly inhibited the proliferation and migration of two highly aggressive CRC cell lines and reduced liver and lung metastasis in vivo. Mechanistically, we revealed that circHERC4 inactivated the tumor suppressor, miR-556-5p, leading to the activation of CTBP2/E-cadherin pathway which promotes tumor metastasis in CRC.
CircHERC4 exerts critical roles in promoting tumor aggressiveness through miR-556-5p/CTBP2/E-cadherin pathway and is a prognostic biomarker of the disease, suggesting that circHERC4 may serve as an exploitable therapeutic target for patients with CRC.
结直肠癌患者死亡的主要原因是转移。越来越多的证据表明,circRNA 在癌症的发生和发展中起着关键作用。然而,协调癌症转移的 circRNA 的潜在分子机制仍不清楚,需要进一步阐明。
使用两对 CRC 和相邻正常组织通过 circRNA-seq 筛选上调的 circRNA;然后,应用细胞侵袭实验来确认具有功能侵袭相关的 circRNA。根据上述方法,选择 circHERC4(hsa_circ_0007113)进行进一步研究。接下来,我们在大量 CRC 患者中研究了 circHERC4 的临床意义。在 CRC 细胞系和动物异种移植研究中研究了 circHERC4 的致癌活性。最后,我们探讨了 circHERC4 作为恶性驱动因子的分子机制。
我们证明 circHERC4 在 CRC 组织中异常升高(P<0.001),并且与淋巴结转移和晚期肿瘤分级呈正相关(P<0.01)。值得注意的是,circHERC4 的表达与 CRC 患者的生存不良相关。沉默 circHERC4 可显著抑制两种高度侵袭性 CRC 细胞系的增殖和迁移,并减少体内肝和肺转移。机制上,我们揭示了 circHERC4 使肿瘤抑制因子 miR-556-5p 失活,导致 CTBP2/E-钙粘蛋白通路的激活,从而促进 CRC 中的肿瘤转移。
circHERC4 通过 miR-556-5p/CTBP2/E-钙粘蛋白通路在促进肿瘤侵袭性方面发挥关键作用,并且是疾病的预后生物标志物,表明 circHERC4 可能成为 CRC 患者可利用的治疗靶标。